Troubles for Industry Veteran Diplomat Began Few Years Ago

Diplomat Pharmacy, Inc.’s sale to OptumRx (see story, p. 1) will mark the end of a specialty pharmacy that is nearly half a century old.

Diplomat began operations in 1975 as a small, regional operation, and, in 2014, it made the decision to go public (RSP 7/14, p. 1). At the time, the company was the fourth largest specialty pharmacy in the U.S., and the move was hailed by industry experts. Diplomat made multiple acquisitions to expand into areas such as bleeding disorders, immune globulin therapy and hepatitis C (RSP 7/15, p. 1).

Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Contributors:

Peter Johnson,

Leslie Small,

Jinghong Chen,

Related Posts

a-businessman-touching-screen
May 12

Do Pharma/PBM Contracts Play Role in Drugmakers’ Revenue Leakage?

READ MORE
a-doctor-speaking-to-a-patient
May 12

Novartis’ Pluvicto Brings New Mechanism of Action to mCRPC Options

READ MORE
an-elderly-looking-outside
May 12

Study Finds PBC Drug’s Real-World, Trial Side Effects Are Similar

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today